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The achievements of drug development dur-
ing last decades have been greater than ever
before. The new concepts of the dosage forms
design and innovation of manufacturing technolo-
gy have a strong influence on the pharmaceutical
development of new drugs. Over the years, various
technologies have been developed to achieve the
formulation with predefined properties, from the
conventional to the modified release dosage
forms. Quality of the dosage forms should be build
in the drug product based on the understanding of
many aspects related to the physical, chemical and
biopharmaceutical properties of the active phar-
maceutical ingredients (APIs), excipients proper-
ties and manufacturing processes GMP. Due to the
modernized GMP regulations, understanding of
the factors that influence the pharmaceutical prod-
uct quality is of great importance to successful
production.
Novel approaches are proposed especially for
dosage forms suitable for defined population, from
children to elderly patients. Therefore, recently per-
sonalized medicine is challenging study area, and
different concepts for individualized therapy are
proposed. The dosing precision of drug formulations
ensure effectiveness in safe drug therapy. The most
valuable strategy concerns dosage forms with high
dose flexibility and low production costs. 
Recently, considerable attention has been
focused on manufacturing methods of novel dosage
forms with usage of different types of printers.
Three-dimensional (3D)- or two-dimensional (2D)-
printing is rapidly developing. The first 3D-printed
levetiracetam orodispersible tablets (SpritamÆ) was
approved by FDA. It is emphasized that highly pre-
cise ratio of the active ingredient to excipients can
be achieved in controlled manner.
The aim of the paper is to review the usage of
printing techniques in pharmaceutical technology.
Three dimensional printing methods
The term ì3D printingî is related to the
numerous methods of rapid prototyping, that are
used in a process of new product development, mak-
ing it less expensive and less time consuming. 3D
printing is defined by International Standard
Organization (ISO) as: ìfabrication of objects
through the deposition of a material using a print
head, nozzle, or another printer technologyî (1) and
could be referred to a solid freeform fabrication
(SFF) or additive manufacturing (AM), i.e. a
process of forming 3D objects layer-by-layer by
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addition and solidification of raw materials without
using molds or casts (2).
Development of 3D printed objects includes
several steps common for different printing tech-
niques (Fig. 1) (3).
● Construction of 3D object with computer-aided
design (CAD) software. During this phase the
printing method and properties of the printer (e.g.
resolution) should be taken into account.
● Export of 3D model to STL file format, compati-
ble with 3D printer. The STL format, which is an
abbreviation coming from STereoLithography
was originally developed by 3D Systems compa-
ny as a native format for their first stereolithogra-
phy printer commercialized in 1989 (4). STL files
describe triangulated surface geometry of 3D
object, and are currently used not only in the
stereolithography, but also in other 3D printing
methods.
● Import of the STL file to the printer software, and
if necessary, generation of supports to prevent
object collapsing. Printing program slices 3D
model into layers corresponding to printed layers,
and data is transferred as XYZ coordinates to the
printer.
● Layer-by-layer building of object by solidifica-
tion of different raw materials dependent of the
used 3D printing method. 
● Sometimes, additional post processing steps, such
as drying, smoothing, and removing of supports
or residual powder are performed.
There are several 3D printing methods with
different object building systems based on:
● ink solidification or ink binding of a free powder,
● solidification of a photopolymer in the presence
of light,
● extrusion of material ñ fused deposition modeling
(FDM) or syringe pressure systems, that can be
used in the area of drug delivery development
(Fig. 2) (5).
The first 3D printing method used for the
development of pharmaceutical dosage forms was
deposition of ink on the powder bed ñ drop on solid
deposition (DoS). Droplets of ink with defined
diameter are sprayed by print head on a surface of
free powder, where they bind its particles into layer,
whereas unbound powder is used as a scaffolding
for overhang faces or porous structures. First print
heads used in this process were commercially avail-
able heads from inkjet printers. Droplets of ink are
Figure 1. The development process of printing 3D model
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created with thermal or piezoelectric system (Fig.
3). In the case of thermal print heads, inks should be
based on a volatile solvents, because heating resistor
rapidly heats them in the chamber and growing bub-
bles of air generate the ink ejection force (6). In
piezoelectric print heads, an electric pulse bends
piezoelectric element and pushes out droplets of ink,
which allows the usage of various types of inks (7).
Active drug substance can be dissolved in ink or
mixed with a powder bed. Powder properties (e.g.,
topology, particle size, porosity, wettability, reactiv-
ity with the ink), ink properties (e.g., viscosity, type
of solvent, binding polymers) and process parame-
ters (droplet size, spray rate) are essential for print-
ed layer height and product properties. 
In drop on drop (DoD) deposition method,
droplets of ink solidify layer-by-layer on each other
without powder addition (Fig. 3). Usually ink con-
tains additives improving building properties e.g.,
polymers, waxes, suspensions. Unlike in DoS, layer
height is smaller than droplet size and object could
be printed with higher resolution (5).
The most precise 3D printing method is stereo-
lithography, which involves polymerization of pho-
topolymer in the presence of light (Fig. 4). A geom-
etry of the object is transferred by the UV light at the
surface of photoresin. Build platform is lowered and
another layer is created. Its height depends on the
light energy, resin properties and platform move-
ment. The main weakness of this method is limited
number of nontoxic resins and high energy of UV
light which is commonly used (3, 4). 
In the extrusion based system, APIs are mixed
with polymers and object layers are built with the
mixture continuously ejected through the nozzle
(Fig. 5). Fused deposition modeling (FDM), also
known as fused filament fabrication (FFF) is one of
the rapid prototyping methods used in many differ-
ent fields, in recent years also in pharmaceutical
technology and medicine. The idea of this method is
based on the application of successive layers of
fused material by precisely controlled nozzle of the
3D printer. The thermoplastic polymer in the fila-
ment form of specified dimeter is used to construct
the object. There is a variety of filaments commer-
cially available, such as: ABS, PLA, PVA, Nylon
etc. but only few of them can be applied in pharma-
ceutical development. 
A schematic construction of FDM 3D printer is
presented in Figure 4. The most important element
of the system is printing head equipped with one or
more nozzles that can be moved in two dimensions
Figure 2. Diversity of 3D printing technologies
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Figure 3. The printing mechanism with DoD and DoS printing methods
Figure 4. Stereolithographic printing system
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e.g., along the y- and z-axes. The working tempera-
ture of nozzle is controlled in the wide range,
because of different melting points of printing mate-
rials. Depending on the system, there can be one,
two or even three nozzles attached to the printing
head, which gives the opportunity to print with dif-
ferent materials varying in melting temperatures and
physical properties such as water solubility. There
are only a few companies offering printing heads
containing one nozzle able to print with two materi-
als with similar melting temperatures. The polymer
materials are fused and mixed in the printing head
with a fixed ratio and the printing is carried out with
a combined material. The diameter of a standard
nozzle is 0.4 mm, but in order to improve the quali-
ty of the printout, it can be exchanged to a smaller
one, such as 0.3 mm or 0.2 mm. Another important
element of the printer is the build platform (also
called printing table) which should be capable to be
heated, because some materials better stick to its
surface when it is hot. The printing table is also
movable in one, two or three axes depending on the
system. Build platform in the presented 3D printer is
moving along x-axis. In order to improve the poly-
mer sticking to the table, it can be covered with a
special texture tape BuildTakTM. The printing space
is limited by a minimum and maximum position of
the nozzle tip within the 3 dimensions in relation to
the printing table. Different FFF printers have
opened or closed printing areas. The second ones are
more suitable, especially for printing with polymers
that are shrinking upon cooling. 
There are many 3D printing process parame-
ters that need to be considered. The temperature of
the nozzle is dependent on the kind of a polymer and
it should be set up near to its melting point, while
printing table temperature depends on the material
sticking properties. Printing speed have to be select-
ed carefully depending on the used system, polymer,
complexity of the printed object and expected qual-
ity of the printout. Typically 40 mm/s speed is used,
but some printers can go up to 150 mm/s or even
faster. Height of the layers generally affects the
printing precision in the way, that the higher the
layer is, the lower quality of the object will be.
There are also some software parameters that have
to be taken into consideration. The infill density is
not so obvious parameter. During the object design,
it seems to have a solid form but during the printing
only the external walls, its bottom and top are solid.
It is caused by filament material saving. The object
can be printed with infill density from 0% to 100%
which means that it can be empty or completely
filled with material. The infill can also possess dif-
Figure 5. Fused deposition modeling ñ construction and mechanism of action
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ferent geometries e.g., rectilinear or honeycomb. All
of the parameters can affect the quality and proper-
ties of printed objects.
As previously mentioned, filaments that are
available on the market have limited application in
the pharmaceutical technology. Much more oppor-
tunities are given with fabrication of a specific fila-
ment by hot-melt extrusion in own laboratory. It
allows to incorporate the API directly into the fila-
ment. It is also attractive method, because the
process of hot-melt extrusion is well known in the
pharmaceutical technology. This preparation
method was utilized by Holl‰nder et al. to produce
poly(ε-caprolactone) (PCL) based filaments with
incorporated indomethacin (8). Filaments with three
different drug loading, i.e. 5%, 15% and 30% were
prepared. It was stated that the amount of
indomethacin in the filament significantly affected
the properties of the filament, quality of the printed
prototype and indomethacin release characteristics.
Hot-melt extrusion was used also to produce
polyvinyl alcohol (PVA) filament containing parac-
etamol (9) and ethylene vinyl acetate (EVA) fila-
ment with indomethacin (10).
Other alternative to introduce the drug into the
polymer is impregnation of filament with API in the
form of solution in volatile solvent (11). The impreg-
nation of the PVA filament with a prednisolone
methanolic solution resulted in the loading efficien-
cy as low as 1.9%, and required application of organ-
ic solvents. It was also stated that despite that the
prednisolone was in the amorphous state in the print-
ed tablets, its dissolution was prolonged. The disso-
lution profiles were similar regardless of the dose of
the API, and a quality of the tablets was evaluated
according to the time after which more than 80% of
the drug substance was released. Over 80% of pred-
nisolone was dissolved from 3D printed tablets with
2 and 3 mg of API after 12 h and after 18 h from the
tablets containing 4 ñ 10 mg of the active substance.
There is a great number of studies based on the
non-pharmaceutical grades of filament material.
Many of those are prepared from commercially
available filaments shredded and re-extruded with
the API or impregnated with it. That has to be high-
lighted, that the second extrusion of the same mate-
rial could change its properties dramatically and that
the filament material is not fully specified as it
should be for pharmaceutical applications. Boetker
et al. have combined a commercial filament with
pharma grade hydroxypropyl methylcellulose in
hot-melt extrusion process to modify the solubility
of the material and improve the dissolution proper-
ties of the nitrofurantoin (12).
The additional advantage of this particular
printing method, significant to drug manufacturing
is simple control of the dose of the active substances
by changing the volume of the designed drug form
(11) or in some cases by modification of the infill
ratio of the drug form. Usage of multi-nozzle 3D
printers allows the production of drugs containing
more than one active ingredient, also incompatible
ones, which is a big advantage in the age of com-
bined pharmaceuticals. A wide range of materials,
that can be used for the preparation of 3D printing
filament is available in pharmaceutical grade with
different properties such as water solubility. A sig-
nificant advantage is the possibility to obtain amor-
phous drug during a printing process, which allows
to improve the dissolution characteristics of poorly
soluble drugs. However, this matter has to be further
fundamentally investigated due to the stability
issues (13).
Overview of the latest research achievements
Current studies are focused on the application
of 3D printing technology to the pharmaceutical
dosage forms manufacturing, mostly solid oral
dosage forms, such as conventional and modified-
release tablets, implants, orodispersible tablets and
films. The most commonly used printing techniques
are based on the extrusion process (Table 1).
As for now, tablets are the most favored dosage
form. In spite of it, poor patient compliance in drug
administration leading to ineffective pharmacother-
apy is stated. It could be changed by the develop-
ment of different types of tablets in size, shape and
design.
Many diseases, encountered particularly by
geriatric patients, require therapy with a numerous
active pharmaceutical ingredients administered sep-
arately. Incorporating several APIs into one dosage
form may significantly improve patient compliance.
3D printing technique based on the room tempera-
ture extrusion process was utilized to obtain tablets
named by authors ìpolypillî, containing captopril,
nifedipine and glipizide characterized by different
release mechanisms. A soft paste of each component
of tablet, i.e., the API formulation feedstocks with
different HPMC concentration, the tablet shell paste
and the joining layer feedstock were prepared sepa-
rately and extruded on a glass slide. The printed
tablet was consisted of captopril osmotic pump,
joining layer, nifedipine and glipizide in sustained
release form (Fig. 6). Fast disintegration of joining
layer allowed to split tablet into two separated parts
with various release mechanism, captopril with zero
order kinetic and nifedipine and glipizide with first
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Table 1. Dosage forms prepared by 3D printing.
Dosage form Active ingredient Excipients Ref.
3D printing
Fused deposition modeling (FDM)
Caplet
Acetaminophen
Caffeine
PVA filament 9
Caplet Budesonide PVA filament 14
Capsule Acetaminophen
PLA filament, HPC, PEG 1500, polyvinyl alcohol- 
polyethylene glycol graft copolymer Brilliant Blue
15
Tablet
5-Aminosalicylic acid
4-Aminosalicylic acid
PVA filament, absolute ethanol 16
Tablet Acetaminophen PVA filament 17
Tablet Fluorescein sodium PVA filament, absolute ethanol 18
Implant γ-Indomethacin Ethylene vinyl acetate 10
T-shaped  
intrauterine γ-Indomethacin Ethylene vinyl acetate 10
systems
Pressure assisted syringe
Bilayer tablet Guaifenesin
HPMC, poly(acrylic acid), microcrystalline cellulose, 
sodium starch glycolate
19
Aspirin
Hydrochlorothiazide PVP, lactose, D-mannitol, sodium starch glycolate, 
Tablet "polypill" Atenolol HPMC, milli-Q purified water, cellulose acetate, 20
Pravastatin sodium PEG 6000, acetone, DMSO
Ramipril
Captopril HPMC, sodium chloride, D-mannitol, croscarmellose 
Tablet "polypill" Glipizide sodium, microcrystalline cellulose, sodium starch 21
Nifedipine glycolate, PVP K30, tromethamine, cellulose acetate, 
PEG 6000, acetone, DMSO
Ammonio methacrylate copolymer type A, ammonio 
Tablet Theophylline methacrylate copolymer type B, HPC, triethyl citrate, 22
triacetin
Drop on solid deposition
Implant Levofloxacin Poly(L-lactic acid), ethanol, acetone 23
Implant
Rifampicin 
Isoniazid
Poly(DL-lactic acid), methanol, acetone, purified water 24
Microcystalline cellulose, basic butylated methacrylate 
Tablet Chlorpheniramine maleate copolymer, ammonio methacrylate copolymer type A, 25
ethanol
Microcrystalline cellulose, spray dried lactose, methacrylic
Tablet Diclofenac sodium acid - methyl methacrylate copolymer, ammonio 
methacrylate copolymer type A, PVP K25, methanol, 25
acetone, ethanol
ODT Acetaminophen
Colloidal silicon dioxide, PVP K30, lactose, mannitol, 
alizarin yellow
26
Colloidal silicon dioxide, glycerin, mannitol, 
ODT Levetiracetam microcrystalline cellulose, polysorbate 20, povidone, 
sucralose, butylated hydroxyanisole, and natural and 27
artificial spearmint flavor
Drop on drop deposition
Mucosal thin Cetirizine hydrochloride
films Diphenylhydramine hydrochloride Basic butylated methacrylate copolymer, ethanol 28
Ibuprofen
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order kinetic. The drug release rate was controlled
by the amount of HPMC (21).
Modified-release budesonide caplets (rounded,
hard capsule-shaped tablets) were fabricated using
FDM 3DP, combined with hot melt extrusion (HME)
and fluid bed coating. The PVA filament containing
API was prepared through the grinding of the com-
mercial PVA filament to obtain fine powder, mixing
with budesonide and then extruding the mixture.
Caplets with 9 mg of API were created with FDM 3D
printer using previously prepared filament. Finally,
printed caplets were coated with a solution of
EudragitÆ L100. The dissolution profile of 3D print-
ed dosage form was compared with profiles of com-
mercially available budesonide prolonged release
tablets (CortimentÆ 9 mg) and hard gelatin capsules
containing gastro-resistant prolonged-release gran-
ules (EntocortÆ CR 3 mg). The dissolution test was
performed in hydrochloric acid for 2 h and in phos-
phate buffer of pH changing during the test for fur-
ther 8 h. All formulations were resistant to acidic
condition, however their dissolution profiles were
different. More than 90% of budesonide was released
from EntocortÆ after 3 h, and 50% and over 80% of
the drug after 10 h from CortimentÆ and 3D printed
caplets, respectively. Gradual drug release in intes-
tinal environment, observed for printed caplets, indi-
cated the possibility of application of printed form in
intestinal inflammatory treatment (14).
Drop on solid deposition printing technique
was used to fabricate pulsed-release implants in
cylindrical shape, containing rifampicin and isoni-
azid used for treatment of bone tuberculosis. Powder
of poly(DL-lactic acid) was used as a carrier materi-
al. It was solidified by binder solution of rifampicin
or isoniazid to obtain alternating 4 layers of each
drug from the center to periphery (Fig. 7). Drug
release was evaluated using in vitro and in vivo tests
ran for 8 weeks. Studies demonstrated that the disso-
lution profiles correlated with the data acquired dur-
ing in vivo test performed with adult rabbits. In dis-
solution studies, peak values were obtained on the
2nd and 22nd day for isoniazid, whereas rifampicin
was releasing slowly for the first 4 days, and maxi-
mum concentration was measured on the 10th and
34th day. Similar results were observed in in vivo
studies. Maximum drug concentration (cmax) of isoni-
azid in bones was reached on the first and 21st day.
In the case of rifampicin, no drug was released for
the first 4 days, and cmax was detected as late as on the
14th and 35th day. Concentration of both drugs in
arterial blood was very low, what indicated that they
were distributed to the bones as a targeted place, and
that side effects could be reduced (24).
Figure 6. Schematic illustration of ìpolypillî tablet
Figure 7. Schematic illustration of pulsed-release implant
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Orally disintegrating dosage forms can over-
come the swallowing problems encountered by
patients with dysphagia.
In 2016 pharmaceutical company Aprecia has
introduced SpritamÆ orodispersible tablets with leve-
tiracetam that disintegrate in a matter of seconds when
taken with a sip of liquid. They were produced with
ZipDoseÆ Technology platform featuring powder-liq-
uid three dimensional printing method which allows
manufacturing of highly porous drugs. Furthermore,
ZipDoseÆ enables to incorporate up to 1000 mg of
active pharmaceutical ingredient and to effectively
mask the unpleasant taste of a drug substance (27).
In recent years, orodispersible films have
gained popularity, especially as a relevant dosage
forms in therapy of pediatric, geriatric, handicapped
or bedridden patients. The most commonly method
used for ODFs preparation is solvent casting.
However, formulation of fast dissolving films with
rapid disintegration and good mechanical properties
is still challenging. This issue may be solved by
using one of the 2D printing technique in ODFs
preparation, i.e. inkjet or flexography printing,
where APIs solution or suspension is deposited onto
a drug-free film (Table 2). 
The influence of films preparation using inkjet
printing and solvent casting methods on their prop-
erties were compared. PVA and carboxymethyl cel-
lulose sodium salt (SCMC) at ratio 1 : 1 were used
as a film forming polymers, and glycerol was added
Table 2. Application of 2D printing technique for films preparation.
Dosage Active 
form ingredient 
Excipients Ref. 
2D printing 
Inkjet printing 
Caffeine
Propylene glycol, ethanol, purified water, edible icing sheets basedODF Loperamide 
on the corn starch, HPC, polyethylene terephthalate films
29
hydrochloride
ODF
Clonidine PVA, carboxymethylcellulose sodium, glycerol, methanol, absolute 
hydrochloride ethanol 
30
ODF
Rasagiline 
mesylate 
Propylene glycol, HPMC, crospovidone, glycerol, purified water 31
ODF Salbutamol sulfate Glycerine, purified water, commercial potato starch film,  32
Purified water, PEGylated poly(lactic-co-glycolic) acid, ethyl 
acetate, PVA, PEG 2000, PEG 3000, PEG 6000, ethanol, glycerol, ODF Sodium picosulfate
pharmaceutical-grade oral film, hydrophobic non porous film, 
33
hydrophilic porous film 
ODF Piroxicam PEG-400, ethanol, edible icing sheets based on the corn starch 34
Extended 
Dexamethasone-release film 
21-phosphate
DL-lactic/glycolic copolymer, PVA 35
disodium
Combining inkjet and flexographic printing
Propranolol Propylene glycol, glycerol, purified water, ethylcellulose, ethanol, 
Controlled hydrochloride alkyl ketene dimer-sized uncoated woodfree paper, triple-coated
release film Riboflavin sodium inkjet paper, double-coated sheet fed offset paper, water 36
phosphate  impermeable polyethylene terephthalate film 
Riboflavin sodium 
phosphateControlled
Propranolol Ethylcellulose, propylene glycol, glycerol, ethanol 37release film
hydrochloride
Theophylline 
Flexographic printing
ODF
Indomethacin
Itraconazole  
Poloxamer 407, purified water, transparency film, rice sheet, rice paper  38
ODF Piroxicam PEG-400l, edible icing sheets based on the corn starch 34
Rasagiline 
ODF mesylate HPMC, crospovidone, glycerol, purified water, HPC, brilliant blue, ethanol  39
Tadalafil   
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as a plasticizer. The casting solution was poured
onto tray and dried in an oven at 30OC. Methanolic
solution of clonidine hydrochloride and glycerol
was printed onto earlier prepared free films to obtain
final product ñ fast dissolving films containing from
7.6, to 250 µg of API per strip with dimension of 2
◊ 2 cm. ODFs with clonidine hydrochloride
obtained in the solvent casting method were pre-
pared by dissolving appropriate amount of API in
PVA:SCMC solution, casting it onto tray, drying at
30OC and cutting into 4 cm2 strips. The printed films
had 4 times lower dose variation and better mechan-
ical parameters than casted films. Films prepared
with solvent casting method were brittle, which was
indicated by the value of Youngís modulus above
1000 MPa, while mechanical parameters of printed
films were more related to placebo. ODFs contain-
ing 90 or 250 µg of clonidine hydrochloride per strip
were evaluated after being exposed to the high tem-
perature and humidity, i.e. 60OC and 75% RH or
30OC and 0-90% RH. In both cases, crystallization
of API was detected only for films prepared by sol-
vent casting method containing higher dose of drug
substance. Furthermore, crystals growth was also
observed in the case of casted films containing 90 µg
of clonidine hydrochloride, subjected to higher
humidity (30). 
Flexographic printing technique was used to
manufacture orodispersible films containing rasagi-
line mesylate or tadalafil. Substrate for printing,
based on the HPMC was prepared by solvent casting
method. The final placebo film was rolled up into
jumbo roll and cut into daughter rolls with a diame-
ter 2 cm x 100 m. An ink solution of rasagiline
mesylate and an ink suspension of tadalafil were
prepared by dissolving or dispersing APIs in ethano-
lic solution of HPC. Four layers of the ink solution
or suspension with blue colorant were deposited
onto free-drug film and cut into strips 3 cm length.
ODFs with diameter 2 cm x 3 cm containing
tadalafil or rasagiline mesylate were also prepared
utilizing solvent casting method. ODFs prepared
using printing technique as well as those prepared
by casting method were flexible and did not break.
Films containing rasagiline mesylate were smooth
and crystallization was not observed regardless the
method of their preparation. ODFs with tadalafil
prepared by casting method were heterogeneous and
large agglomerates and crystals were detected.
Some crystals were also visible in the case of films
produced with flexographic printing, but they were
smaller and homogenously dispersed on the film
surface. Orodispersible films prepared with casting
method were characterized by higher drug concen-
tration compared to the printed films, what indicat-
ed, that flexographic printing could be used only for
manufacturing of ODFs containing low dose of
high-potent drugs (39). 
SUMMARY
The studies presented above, as well as other
numerous researches on the 2D and 3D printing
published in scientific journals during last years, are
the clear evidence of the growing importance of
these methods in different areas of medical sciences
and in pharmaceutical technology. Its growing pres-
ence can be noticeable at the scientific congresses
and in the increasing number of scientific publica-
tions during last years. At the 8th World Meeting on
Pharmaceutics, Biopharmaceutics, and Pharma-
ceutical Technology, held in 2012 in Istanbul,
Turkey, there was only one poster presentation on
the 3D printing technology, one on the 2D printing,
and one lecture describing application of inkjet
printing in the drug technology. During the next
meeting in 2014, there were two posters regarding
this topics. However, in the same meeting held in
the current year the 2D and 3D printing were among
main hot topics of the event, and even the whole ses-
sion on this topic was held, giving overall 6 lectures
on 2D printing and 3 lectures on 3D printing. Poster
sessions included 3 presentations on 2D printing and
4 posters on 3D printing. The recent researches in
this area contained works on the different solid
dosage forms preparation with fused deposition
technology, its application in tissue bioengineering,
inkjet printing as well as methods of preparation of
filaments with active pharmaceutical ingredients,
and qualification of 3D-printers for pharmaceutical
applications.
The growing popularity of 2D and 3D printing
is also noticeable in the remarkably increasing num-
ber of scientific papers published during last few
years. Number of publications containing keyword
ì3D printingî that were registered in the Thomson
Reuters Web of Science database grew from 165 in
2010 to 1336 in 2015. Among them 49, and 447,
respectively, were related to the life sciences. No
articles regarding application of 3D printing in the
pharmacy were published in 2010, but in 2015 their
number increased to 22. Similar results can be found
for other keywords related to this topic, i.e. ìfused
deposition modelingî, ìfused filament fabricationî
or ìthree dimensional printingî. This demonstrates
that the application of 2D- and 3D-printing technol-
ogy to the area of pharmaceutical sciences is one of
the most innovative directions of future researches
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in the field, giving the new possibilities to the
dosage form development and production.
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